Unitaid is investing US$59 million in the IMPAACT4TB (Increasing Market and Public health outcomes through scaling up Affordable Access models of short Course preventive therapy for TB) project.
 
 
 

This study is led and sponsored by the Aurum Institute. The study is a parallel, two-part, open-label, individually randomized, pragmatic trial among HIV-positive individuals.
 
 
 
 

The purpose of this study is to compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing confirmed or probable active tuberculosis (TB) during 96 weeks of follow-up among high-risk household contacts (HHCs) of
adults with multidrug-resistant
tuberculosis (MDR-TB)
(index cases).

The TB Sequel consortium is a research consortium that was built on pre-existing research collaborations within the TTU-TB of the German Center for Infection Research (DZIF) and between LMU and different African Sites (such as the PanACEA-consortium or
MaTuTU-project).
 
 

EHPSA commissioned Aurum Research Institute to assess the policies and practices related to HIV and TB data collection and surveillance in correctional facilities of Malawi, Namibia, Lesotho, Swaziland, and Zambia.
 
 
 
 

The Aurum Institute collaborates with CHAPS and the Bantwana Initiative to increase voluntary medical male circumcision VMMC among adolescent boys and young men ages 10-29 as a mechanism for HIV prevention in Eswatini.
 
 
 
 

CUT-TB (Community and Universal Testing for TB among contacts) is a 4-year EDCTP funded cluster-randomised pragmatic that is being conduct in South Africa, Tanzania and Lesotho. The study  aims to measure effectiveness of universal testing compared to
standard TB screening for detection of TB among
household and community contacts.

The Opt4TPT (Optimising the delivery cascade for tuberculosis preventive treatment among people living with HIV) study is a three-year programmatic assessment of TPT delivery across three countries, namely Ethiopia, South Africa and Zimbabwe,
to generate critical knowledge to improve TPT
uptake, implementation and outcomes.

DRTB-HDT The EU-funded DRTB-HDT (Stratified Host-Directed Therapy for Drug Resistant Tuberculosis) project will determine if two adjunctive host-directed therapies can prevent the poor outcomes of treatment in cases of RIF-R TB. Patients with RIF-R TB and other risk factors for poor outcome will participate in a randomised, controlled, three-armed multicentre trial.
 

IMPAACT4C19 (Improving Public Health Outcomes through Enhancing Accelerated Access to Care and Treatment Innovation for COVID-19) aims to improve access to COVID-19 related quality and affordable diagnostic and therapeutic tools in 5 countries through policy and regulatory support, technical support to ministries of health, supply chain and procurement assistance, and demand generation in communities. During grant implementation,
evidence will be generated to support scale-up and
further catalytic uptake in existing countries and
beyond.